Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Evercore ISI Reiterates $70 PT on Intellia Therapeutics (NTLA), 'Year of P3 execution'
February 23, 2024 9:27 AM ESTEvercore ISI analyst Liisa Bayko reiterated an Outperform rating and $70.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "2024 will be a year of execution for NTLA with P3 for NTLA-2001 in ATTR-CM ongoing while preparing P3 for ATTR-PN and HAE. P3 MAGNITUDE study for NTLA-2001 in ATTR-CM kicked off end of last year and will dose the first patient in 1Q. The trial size is slightly greater than that of HELIOS-B (ALNY). We estimate enrollment to complete around year-end 2024 and topline readout in 2H27.... More
Citi on Intellia Therapeutics (NTLA): 'we believe that NTLA-2001 might find its home as a niche offering'
February 23, 2024 9:25 AM ESTCiti analyst David Lebowitz reiterated a Neutral rating and $31.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "Following competitor Alnylams HELIOS-B updates (HERE), mgt. remains confident in the event-driven design of NTLA-2001s Ph3 MAGNITUDE trial. While there are no planned... More
Goldman Sachs Downgrades Intellia Therapeutics (NTLA) to Neutral, 'A quieter 2024 catalyst path'
February 23, 2024 9:19 AM ESTGoldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NASDAQ: NTLA) from Buy to Neutral with a price target of $32.00.
The analyst comments "NTLA reported 4Q EPS and reiterated the near-term catalyst path for NTLAs in vivo CRISPR gene-edited therapies, which include: 1) longer-term Ph1 data from NTLA-2001 in ATTR-cardiomyopathy (ATTR-CM) and... More
